PROTAGONIST THERAPEUTICS INC's ticker is PTGX and the CUSIP is 74366E102. A total of 145 filers reported holding PROTAGONIST THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.11 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $1,455,697 | -34.3% | 87,272 | +8.8% | 0.00% | 0.0% |
Q2 2023 | $2,215,124 | +77.7% | 80,200 | +48.0% | 0.00% | 0.0% |
Q1 2023 | $1,246,600 | +110.8% | 54,200 | 0.0% | 0.00% | – |
Q4 2022 | $591,322 | +75.5% | 54,200 | +35.5% | 0.00% | – |
Q3 2022 | $337,000 | -7.4% | 40,000 | -13.0% | 0.00% | – |
Q2 2022 | $364,000 | -87.8% | 46,000 | -63.6% | 0.00% | -100.0% |
Q1 2022 | $2,995,000 | +90.8% | 126,463 | +175.5% | 0.00% | 0.0% |
Q4 2021 | $1,570,000 | +93.1% | 45,900 | 0.0% | 0.00% | – |
Q3 2021 | $813,000 | -60.5% | 45,900 | 0.0% | 0.00% | -100.0% |
Q2 2021 | $2,060,000 | +159.8% | 45,900 | +50.0% | 0.00% | – |
Q1 2021 | $793,000 | +40.6% | 30,600 | +9.3% | 0.00% | – |
Q4 2020 | $564,000 | +3.1% | 28,000 | 0.0% | 0.00% | – |
Q3 2020 | $547,000 | +10.7% | 28,000 | 0.0% | 0.00% | – |
Q2 2020 | $494,000 | +333.3% | 28,000 | +73.9% | 0.00% | – |
Q1 2020 | $114,000 | +28.1% | 16,100 | +27.8% | 0.00% | – |
Q4 2019 | $89,000 | -41.1% | 12,600 | 0.0% | 0.00% | – |
Q3 2019 | $151,000 | – | 12,600 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
JOHNSON & JOHNSON | 2,449,183 | $19,373,000 | 4.95% |
Bain Capital Life Sciences Investors, LLC | 2,260,572 | $17,881,000 | 2.10% |
Finepoint Capital LP | 735,126 | $5,815,000 | 2.01% |
Altium Capital Management LP | 365,100 | $2,888,000 | 1.16% |
RTW INVESTMENTS, LP | 4,794,499 | $37,924,000 | 0.98% |
Amitell Capital Pte Ltd | 50,129 | $397,000 | 0.90% |
COWEN AND COMPANY, LLC | 1,065,724 | $8,430,000 | 0.81% |
Tri Locum Partners LP | 155,000 | $1,226,000 | 0.50% |
BVF INC/IL | 1,106,838 | $8,755,000 | 0.42% |
HighVista Strategies LLC | 46,459 | $367,000 | 0.22% |